283 related articles for article (PubMed ID: 31862796)
1.
Quelven I; Monteil J; Sage M; Saidi A; Mounier J; Bayout A; Garrier J; Cogne M; Durand-Panteix S
J Nucl Med; 2020 Jul; 61(7):1058-1065. PubMed ID: 31862796
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Development of CD38-Targeted [
Ghai A; Maji D; Cho N; Chanswangphuwana C; Rettig M; Shen D; DiPersio J; Akers W; Dehdashti F; Achilefu S; Vij R; Shokeen M
J Nucl Med; 2018 Feb; 59(2):216-222. PubMed ID: 29025987
[TBL] [Abstract][Full Text] [Related]
3. Comparison of CD38-Targeted α- Versus β-Radionuclide Therapy of Disseminated Multiple Myeloma in an Animal Model.
Minnix M; Adhikarla V; Caserta E; Poku E; Rockne R; Shively JE; Pichiorri F
J Nucl Med; 2021 Jun; 62(6):795-801. PubMed ID: 33127621
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Development of Near-Infrared-Labeled CD38-Targeted Daratumumab for Optical Imaging of CD38 in Multiple Myeloma.
Cho N; Ko S; Shokeen M
Mol Imaging Biol; 2021 Apr; 23(2):186-195. PubMed ID: 32964391
[TBL] [Abstract][Full Text] [Related]
5. A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma.
Duray E; Lejeune M; Baron F; Beguin Y; Devoogdt N; Krasniqi A; Lauwers Y; Zhao YJ; D'Huyvetter M; Dumoulin M; Caers J
J Hematol Oncol; 2021 Nov; 14(1):183. PubMed ID: 34727950
[TBL] [Abstract][Full Text] [Related]
6. Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma.
Hu Y; Liu H; Fang C; Li C; Xhyliu F; Dysert H; Bodo J; Habermehl G; Russell BE; Li W; Chappell M; Jiang X; Ondrejka SL; Hsi ED; Maciejewski JP; Yi Q; Anderson KC; Munshi NC; Ao G; Valent JN; Lin J; Zhao J
Cancer Res; 2020 May; 80(10):2031-2044. PubMed ID: 32193289
[TBL] [Abstract][Full Text] [Related]
7. ImmunoPET imaging of CD38 in murine lymphoma models using
Kang L; Jiang D; England CG; Barnhart TE; Yu B; Rosenkrans ZT; Wang R; Engle JW; Xu X; Huang P; Cai W
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1372-1381. PubMed ID: 29450576
[TBL] [Abstract][Full Text] [Related]
8. The CD38
Sarkar S; Chauhan SKS; Daly J; Natoni A; Fairfield H; Henderson R; Nolan E; Swan D; Hu J; Reagan MR; O'Dwyer M
Cancer Immunol Immunother; 2020 Mar; 69(3):421-434. PubMed ID: 31919623
[TBL] [Abstract][Full Text] [Related]
9. α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma.
Teiluf K; Seidl C; Blechert B; Gaertner FC; Gilbertz KP; Fernandez V; Bassermann F; Endell J; Boxhammer R; Leclair S; Vallon M; Aichler M; Feuchtinger A; Bruchertseifer F; Morgenstern A; Essler M
Oncotarget; 2015 Mar; 6(7):4692-703. PubMed ID: 25576914
[TBL] [Abstract][Full Text] [Related]
10. 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma.
Chérel M; Gouard S; Gaschet J; Saï-Maurel C; Bruchertseifer F; Morgenstern A; Bourgeois M; Gestin JF; Bodéré FK; Barbet J; Moreau P; Davodeau F
J Nucl Med; 2013 Sep; 54(9):1597-604. PubMed ID: 24003167
[TBL] [Abstract][Full Text] [Related]
11. CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging.
Ulaner GA; Sobol NB; O'Donoghue JA; Kirov AS; Riedl CC; Min R; Smith E; Carter LM; Lyashchenko SK; Lewis JS; Landgren CO
Radiology; 2020 Jun; 295(3):606-615. PubMed ID: 32255416
[TBL] [Abstract][Full Text] [Related]
12. CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma.
Morandi F; Horenstein AL; Costa F; Giuliani N; Pistoia V; Malavasi F
Front Immunol; 2018; 9():2722. PubMed ID: 30546360
[TBL] [Abstract][Full Text] [Related]
13. Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands.
Díaz-Tejedor A; Rodríguez-Ubreva J; Ciudad L; Lorenzo-Mohamed M; González-Rodríguez M; Castellanos B; Sotolongo-Ravelo J; San-Segundo L; Corchete LA; González-Méndez L; Martín-Sánchez M; Mateos MV; Ocio EM; Garayoa M; Paíno T
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731936
[TBL] [Abstract][Full Text] [Related]
14. CD38 as a PET Imaging Target in Lung Cancer.
Ehlerding EB; England CG; Jiang D; Graves SA; Kang L; Lacognata S; Barnhart TE; Cai W
Mol Pharm; 2017 Jul; 14(7):2400-2406. PubMed ID: 28573863
[TBL] [Abstract][Full Text] [Related]
15. B7-H3-targeted
Kasten BB; Arend RC; Katre AA; Kim H; Fan J; Ferrone S; Zinn KR; Buchsbaum DJ
Nucl Med Biol; 2017 Apr; 47():23-30. PubMed ID: 28104527
[TBL] [Abstract][Full Text] [Related]
16. Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb.
Boudousq V; Bobyk L; Busson M; Garambois V; Jarlier M; Charalambatou P; Pèlegrin A; Paillas S; Chouin N; Quenet F; Maquaire P; Torgue J; Navarro-Teulon I; Pouget JP
PLoS One; 2013; 8(7):e69613. PubMed ID: 23922757
[TBL] [Abstract][Full Text] [Related]
17. CD38-specific nanobodies allow
Pape LJ; Hambach J; Gebhardt AJ; Rissiek B; Stähler T; Tode N; Khan C; Weisel K; Adam G; Koch-Nolte F; Bannas P
Front Immunol; 2022; 13():1010270. PubMed ID: 36389758
[TBL] [Abstract][Full Text] [Related]
18. CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.
Green DJ; O'Steen S; Lin Y; Comstock ML; Kenoyer AL; Hamlin DK; Wilbur DS; Fisher DR; Nartea M; Hylarides MD; Gopal AK; Gooley TA; Orozco JJ; Till BG; Orcutt KD; Wittrup KD; Press OW
Blood; 2018 Feb; 131(6):611-620. PubMed ID: 29158362
[TBL] [Abstract][Full Text] [Related]
19. CD38-Targeted Theranostics of Lymphoma with
Kang L; Li C; Rosenkrans ZT; Huo N; Chen Z; Ehlerding EB; Huo Y; Ferreira CA; Barnhart TE; Engle JW; Wang R; Jiang D; Xu X; Cai W
Adv Sci (Weinh); 2021 May; 8(10):2001879. PubMed ID: 34026426
[TBL] [Abstract][Full Text] [Related]
20. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
[No Abstract] [Full Text] [Related]
[Next] [New Search]